Profili Nicia I, Castelli Roberto, Manetti Roberto, Sircana Marta C, Pagni Michela, Sechi Gemma Lisa, Gidaro Antonio, Cossu Costantino, Bella Francesco, Delitala Alessandro P
Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital, 20157 Milan, Italy.
Biomedicines. 2025 Mar 15;13(3):720. doi: 10.3390/biomedicines13030720.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other specific outcomes, particularly at the cardiovascular level. Indeed, due to their diuretic effect, SGLT2i improve the clinical control of chronic heart failure and reduce the risk of rehospitalization. In addition, other studies reported a protective effect on major cardiovascular events and mortality. More recently, it has been suggested that the prescription of SGLT2i after an acute myocardial infarction may have positive effects due to their possible effect on inflammation, arrhythmias, and ventricular remodeling. Here, we reviewed studies focused on SGLT2i after an acute myocardial infarction in patients treated with percutaneous coronary intervention.
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）是一类最初开发用于治疗2型糖尿病的特定药物。随后的研究表明，它们的作用不仅限于血糖控制，还可能对其他特定结局产生积极影响，尤其是在心血管方面。事实上，由于其利尿作用，SGLT2i可改善慢性心力衰竭的临床控制并降低再次住院风险。此外，其他研究报告了对主要心血管事件和死亡率的保护作用。最近，有人提出急性心肌梗死后使用SGLT2i可能因其对炎症、心律失常和心室重塑的潜在作用而产生积极影响。在此，我们回顾了针对接受经皮冠状动脉介入治疗的患者急性心肌梗死后使用SGLT2i的研究。
